Key Highlights

Risk & Performance

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

25.0%

1 terminated/withdrawn out of 4 trials

Success Rate

66.7%

-19.9% vs industry average

Late-Stage Pipeline

50%

2 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed trials have results

Key Signals

1 with results

Phase 3

2(66.7%)

Phase 2

1(33.3%)

3Total

Phase 3(2)

Phase 2(1)

Loading network data...

Showing 4 of 4 trials

Expanded Access Program for Patients at Risk for Catheter-related Infections Who Are Not Eligible for DefenCath® Clinical Trials

Role: lead

Study Assessing Safety & Effectiveness of a Catheter Lock Solution in Dialysis Patients to Prevent Bloodstream Infection

Role: lead

Efficacy and Safety of Deferiprone in Patients With Chronic Kidney Disease Undergoing a Cardiac Catheterization and Receiving Contrast Agent

Role: lead

Deferiprone for the Prevention of Contrast-Induced Acute Kidney Injury

Role: lead

All 4 trials loaded